44 completed, 15 recruiting, 12 terminated, 11 active not recruiting. 94 Phase 2, 12 Phase 1, 11 Phase 3.
Follow Primary Dysautonomias: new trials by email Literature Review of Primary Dysautonomias trials Research Report on Primary Dysautonomias
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open-Label Access to ATH434 for Patients Who Completed Study ATH434-201 in France ATH434 - Multiple System Atrophy | Phase 2 | Enrolling by invitation | Alterity Therapeutics | 7 | 2026-10-01 | 2026-10-09 |
| Autologous Stem Cell Therapy in Patients With Multiple System Atrophy MSCs, Placebo - MSA - Multiple System Atrophy, MSA | Phase 2 | Not yet recruiting | Biocells Medical | 50 | 2026-09-01 | 2026-03-11 |
| Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial Tributyrin, Placebo - Parkinson Disease, Multiple System Atrophy | Phase 1 / Phase 2 | Recruiting | Prabesh Kanel | 15 | 2026-09-01 | 2026-10-07 |
| Efficacy and Safety of Butylphthalide in the Treatment of Multiple System Atrophy 3-N-butylphthalide - Multiple System Atrophy | Phase 2 / Phase 3 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 150 | 2026-08-27 | 2026-10-16 |
| NORTHERA (DROXIDOPA) for Dysautonomia in Pediatric Survivors of Menkes Disease Droxidopa Oral Product, Placebo Control - Menkes Disease | Phase 1 / Phase 2 | Recruiting | Stephen G. Kaler | 6 | 2026-08-10 | 2026-10-05 |
| Beta-3 Enhanced Autonomic Therapy for POTS Mirabegron, Placebo - Postural Orthostatic Tachycardia Syndrome (POTS) | Phase 2 | Not yet recruiting | Cedars-Sinai Medical Center | 36 | 2026-05-01 | 2026-05-13 |
| CE-STAND: Cervical Epidural STimulation After Neurologic Damage Epidural Spinal Cord Stimulation System - Spinal Cord Injury | Phase 1 / Phase 2 | Recruiting | University of Minnesota | 36 | 2026-03-15 | 2026-03-27 |
| Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS To Measure levels of circulating monocyte/ T cell doublets at Baseline, To measure levels of circulating monocyte/ T cell doublets after 28 days of 2 HOBA treatment, To measure levels of circulating monocyte/ T cell doublets after 28 days of Placebo treatment - Post-Acute COVID-19 Syndrome, Postural Tachycardia Syndrome (POTS) | Phase 2 | Recruiting | Vanderbilt University Medical Center | 50 | 2025-12-18 | 2026-01-22 |
| Restoring Iron Deficiency in POTS Intravenous iron - POTS - Postural Orthostatic Tachycardia Syndrome | Phase 2 | Active not recruiting | Vanderbilt University Medical Center | 12 | 2025-11-24 | 2026-10-13 |
| An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy TEV-56286 - Multiple System Atrophy | Phase 2 | Recruiting | Teva Branded Pharmaceutical Products R&D LLC | 200 | 2025-09-30 | 2026-10-09 |
| Feasibility Study Assessing the Effect of Carbidopa/Levodopa Ratio on Orthostatic Hypotension in Multiple System Atrophy - Parkinsonian Type and Parkinson Disease. Administration of Carbidopa/levodopa - Multi-system Atrophy - Parkinsonian Type, Orthostatic Hypotension, Dysautonomic | Phase 1 / Phase 2 | Recruiting | Julien Bally | 36 | 2025-07-18 | 2026-01-29 |
| A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA) Foralumab Nasal - Multiple System Atrophy | Phase 2 | Recruiting | Tiziana Life Sciences LTD | 5 | 2025-05-19 | 2026-06-10 |
| A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy YA-101, Placebo - Multiple System Atrophy | Phase 2 | Active not recruiting | Dasher Neuroscience Inc. | 75 | 2025-03-03 | 2026-08-19 |
| Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS) REGN7544, Placebo - Postural Orthostatic Tachycardia Syndrome (POTS) | Phase 2 | Completed | Regeneron Pharmaceuticals | 82 | 2024-11-13 | 2026-07-21 |
| Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson's Disease and Patients With Multiple System Atrophy exidavnemab, Placebo Comparator - Parkinson Disease, Multiple System Atrophy | Phase 2 | Completed | BioArctic AB | 38 | 2024-10-24 | 2026-08-21 |
| A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy TEV-56286, Placebo - Multiple System Atrophy | Phase 2 | Active not recruiting | Teva Branded Pharmaceutical Products R&D LLC | 349 | 2024-10-02 | 2026-10-09 |
| LIFT: Life Improvement Trial Pyridostigmine, Low-Dose Naltrexone, Placebo - ME/CFS, Long COVID | Phase 2 | Recruiting | Brigham and Women's Hospital | 160 | 2024-09-10 | 2026-10-15 |
| SalT Supplementation in Older Adults With Orthostatic Intolerance Disorders Salt supplementation (encapsulated sodium chloride) - Orthostatic Hypotension | Phase 2 | Active not recruiting | University of Galway | 42 | 2024-07-09 | 2026-06-22 |
| Dexmedetomidine Sublingual Film for the Ambulatory Treatment of Hyperadrenergic Autonomic Crisis in Patients With Familial Dysautonomia Matching placebo, Dexmedetomidine - Familial Dysautonomia | Phase 2 | Enrolling by invitation | NYU Langone Health | 15 | 2024-07-01 | 2026-04-13 |
| Pilot Study of Dexmedetomidine Sublingual Film for the Ambulatory Treatment of Hyperadrenergic Autonomic Crisis in Patients With Familial Dysautonomia Dexmedetomidine Sublingual - Familial Dysautonomia | Phase 2 | Active not recruiting | NYU Langone Health | 5 | 2024-06-01 | 2026-03-04 |
Showing 20 of 94. Sign in to see all of them.
Multiple System Atrophy (35) · Hypotension, Orthostatic (23) · Postural Orthostatic Tachycardia Syndrome (20) · Parkinson Disease (13) · Orthostatic Intolerance (9) · Syncope (7) · Syncope, Vasovagal (7) · Pure Autonomic Failure (6) · Shy-Drager Syndrome (6) · Spinal Cord Injuries (6) · Autonomic Nervous System Diseases (5) · Dysautonomia, Familial (5) · Neurodegenerative Diseases (4) · Post-Acute COVID-19 Syndrome (4)
Nervous System Diseases (94) · Autonomic Nervous System Diseases (89) · Central Nervous System Diseases (49) · Brain Diseases (43) · Neurodegenerative Diseases (43) · Orthostatic Intolerance (42) · Basal Ganglia Diseases (41) · Synucleinopathies (39) · Movement Disorders (38) · Cardiovascular Diseases (32) · Pathological Conditions, Signs and Symptoms (31) · Vascular Diseases (30) · Hypotension (26) · Neurologic Manifestations (22)
Droxidopa (9) · Midodrine (6) · Pyridostigmine Bromide (5) · Carbidopa (3) · Immunoglobulins, Intravenous (3) · Insulin (3) · Ivabradine (3) · Propranolol (3) · Saline Solution (3) · Sodium Chloride (3) · Tilt-Table Test (3) · 8-hydroxyquinazolin-4(3H)-one (2) · ATH434 (2) · Atomoxetine Hydrochloride (2) · Dexmedetomidine (2)
NYU Langone Health (6) · Mayo Clinic (5) · National Institute of Neurological Disorders and Stroke (NINDS) (4) · Vanderbilt University Medical Center (4) · Alterity Therapeutics (3) · Cedars-Sinai Medical Center (3) · James J. Peters Veterans Affairs Medical Center (3) · University of Calgary (3) · Beth Israel Deaconess Medical Center (2) · Brigham and Women's Hospital (2) · Teva Branded Pharmaceutical Products R&D LLC (2) · US Department of Veterans Affairs (2) · University Hospital, Toulouse (2) · Vanderbilt University (2) · Yonsei University (2)
United States (65) · France (10) · Italy (8) · Canada (6) · Japan (6) · Spain (6) · Germany (5) · United Kingdom (5) · Austria (3) · Israel (3) · Portugal (3) · South Korea (3) · China (2) · Denmark (2) · Poland (2)
Alejandra Gonzalez-Duarte, MD (2) · Cyndya Shibao, M.D (2) · David Systrom, MD (2) · Horacio C Kaufmann, MD (2) · Italo Biaggioni, MD (2) · Jill Wecht, EdD (2) · Michele Tagliati, MD, FAAN (2) · Olivier Rascol, MD (2) · Roy Freeman, MD (2) · Satish R Raj, MD MSCI (2) · William Bauman, MD (2) · Wolfgang Singer, M.D. (2) · Alessandro Filla, MD (1) · Alfredo J Gamboa, MD (1) · Amie Jones, MD (1)
PMID 21762873, PMID 10214756, PMID 10406987, PMID 10527042, PMID 10853813, PMID 10979878, PMID 11018167, PMID 11076832, PMID 11400186, PMID 11724917, PMID 12498954, PMID 12904089, PMID 15175402, PMID 15345186, PMID 15645531, PMID 15710782, PMID 15779234, PMID 15911704, PMID 16025231, PMID 16442563, PMID 16715205, PMID 16837857, PMID 17190953, PMID 17385265, PMID 17965289, PMID 18079166, PMID 18349024, PMID 19018276, PMID 19651280, PMID 19687359, PMID 20146689, PMID 20188504, PMID 20801263, PMID 20846908, PMID 20887968, PMID 20976736, PMID 21045744, PMID 21421334, PMID 21538520, PMID 21571570, PMID 21700495, PMID 21802993, PMID 22174345, PMID 22321865, PMID 22483040, PMID 22508280, PMID 22522612, PMID 23024438, PMID 23116538, PMID 23160999
2023 (3), 2025 (2), P01NS044233 (2), 2009 (1), 2015 (1), 2018 (1), P01HL056693 (1), R01DK079974 (1), R01HL059459 (1), R01HL071159 (1), R01HL077438 (1), R01HL144568 (1), U54NS065736 (1), UL1TR000445 (1)